Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1964 1
2002 1
2006 2
2007 2
2008 11
2009 7
2010 16
2011 24
2012 27
2013 33
2014 28
2015 21
2016 14
2017 13
2018 12
2019 14
2020 8
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 23878046

210 results
Results by year
Filters applied: . Clear all
Page 1
Use of ecallantide in pediatric hereditary angioedema.
MacGinnitie AJ, Davis-Lorton M, Stolz LE, Tachdjian R. MacGinnitie AJ, et al. Pediatrics. 2013 Aug;132(2):e490-7. doi: 10.1542/peds.2013-0646. Epub 2013 Jul 22. Pediatrics. 2013. PMID: 23878046
EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema.
Levy RJ, Lumry WR, McNeil DL, Li HH, Campion M, Horn PT, Pullman WE. Levy RJ, et al. Ann Allergy Asthma Immunol. 2010 Jun;104(6):523-9. doi: 10.1016/j.anai.2010.04.012. Ann Allergy Asthma Immunol. 2010. PMID: 20568386 Clinical Trial.
Assessment of rebound and relapse following ecallantide treatment for acute attacks of hereditary angioedema.
Bernstein JA, Shea EP, Koester J, Iarrobino R, Pullman WE. Bernstein JA, et al. Allergy. 2012 Sep;67(9):1173-80. doi: 10.1111/j.1398-9995.2012.02864.x. Epub 2012 Jul 5. Allergy. 2012. PMID: 22765833 Clinical Trial.
Response to ecallantide treatment of acute attacks of hereditary angioedema based on time to intervention: results from the EDEMA clinical trials.
Banta E, Horn P, Craig TJ. Banta E, et al. Allergy Asthma Proc. 2011 Jul-Aug;32(4):319-24. doi: 10.2500/aap.2011.32.3440. Allergy Asthma Proc. 2011. PMID: 21781409 Clinical Trial.
Efficacy and safety of ecallantide in treatment of recurrent attacks of hereditary angioedema: open-label continuation study.
Lumry WR, Bernstein JA, Li HH, MacGinnitie AJ, Riedl M, Soteres DF, Craig TJ, Campion M, Iarrobino R, Stolz LE, Pullman WE. Lumry WR, et al. Allergy Asthma Proc. 2013 Mar-Apr;34(2):155-61. doi: 10.2500/aap.2013.34.3653. Allergy Asthma Proc. 2013. PMID: 23484891 Clinical Trial.
Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor.
Schneider L, Lumry W, Vegh A, Williams AH, Schmalbach T. Schneider L, et al. J Allergy Clin Immunol. 2007 Aug;120(2):416-22. doi: 10.1016/j.jaci.2007.04.028. Epub 2007 Jun 7. J Allergy Clin Immunol. 2007. PMID: 17559913 Clinical Trial.
Outcomes after ecallantide treatment of laryngeal hereditary angioedema attacks.
Sheffer AL, MacGinnitie AJ, Campion M, Stolz LE, Pullman WE. Sheffer AL, et al. Ann Allergy Asthma Immunol. 2013 Mar;110(3):184-188.e2. doi: 10.1016/j.anai.2012.12.007. Epub 2013 Jan 5. Ann Allergy Asthma Immunol. 2013. PMID: 23548529 Clinical Trial.
Ecallantide for treatment of acute hereditary angioedema attacks: analysis of efficacy by patient characteristics.
MacGinnitie AJ, Campion M, Stolz LE, Pullman WE. MacGinnitie AJ, et al. Allergy Asthma Proc. 2012 Mar-Apr;33(2):178-85. doi: 10.2500/aap.2012.33.3528. Allergy Asthma Proc. 2012. PMID: 22525395
Prospective, double-blind, placebo-controlled trials of ecallantide for acute attacks of hereditary angioedema.
Stolz LE, Sheffer AL. Stolz LE, et al. Expert Rev Clin Immunol. 2012 Jan;8(1):25-32. doi: 10.1586/eci.11.81. Expert Rev Clin Immunol. 2012. PMID: 22149337 Clinical Trial.
Ecallantide: in acute hereditary angioedema.
Garnock-Jones KP. Garnock-Jones KP. Drugs. 2010 Jul 30;70(11):1423-31. doi: 10.2165/11205850-000000000-00000. Drugs. 2010. PMID: 20614949 Review.
210 results
Jump to page
Feedback